Amends the Public Health Service Act to prevent biologics from being treated as biological products based on inactive proteins.
The Protecting Equal Access to Thyroid Act of 2026, or PEAT Act of 2026, amends the Public Health Service Act to prohibit the treatment of a biologic as a biological product solely based on the presence of a protein that is a clinically inactive component in the biologic. This change aims to ensure that such biologics are not unfairly regulated or restricted due to the presence of inactive proteins.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.